M. Wouter Dercksen

1.3k citations
38 papers · 862 · h-index 12

Impact in

  • Oncology top 10%
    • HER2/EGFR in Cancer Research
    • Lung Cancer Research Studies
    • Cancer Risks and Factors
  • Cancer Research
    • Breast Cancer Treatment Studies

Papers in

  • Oncology 15
    • HER2/EGFR in Cancer Research 7
    • Cancer Treatment and Pharmacology 3
  • Cancer Research 8
    • Breast Cancer Treatment Studies 7
Co-authors
Saskia Houterman (2 shared papers)Harm R. Haak (2 shared papers)Lonneke V. van de Poll‐Franse (1 shared paper)M.L.G. Janssen‐Heijnen (1 shared paper)J.W.W. Coebergh (1 shared paper)Agnès J. van de Wouw (14 shared papers)Maaike de Boer (13 shared papers)Vivianne C. G. Tjan‐Heijnen (18 shared papers)
Journals
Breast Cancer Research and Treatment (6 papers)Annals of Oncology (3 papers)European Journal of Cancer (2 papers)The Breast (2 papers)Supportive Care in Cancer (2 papers)
Partner nations
NetherlandsUnited StatesGermany

In The Last Decade

M. Wouter Dercksen

36 papers receiving 853 citations

Peers

M. Wouter Dercksen
Comparison fields: 5 of 63
  • Oncology 327
  • Cancer Research 125
  • Pulmonary and Respiratory Medicine 183
  • Urology 20
  • Epidemiology 99
Replace María Apellániz-Ruiz with:
María Apellániz-Ruiz Spain
Ramón Palmero Spain
Takeshi Tomoda Japan
Friedemann Zengerling Germany
Matthew R. Zibelman United States
Gareth Davies United Kingdom
Tsunehiro Ishida Japan
Ertao Zhai China
A. Robinson United Kingdom
Delphine Amsellem‐Ouazana France
M. Wouter Dercksen relative to María Apellániz-Ruiz Spain María Apellániz-Ruiz's profile →
Citations per field
00.5×2×3.3×
María Apellániz-Ruiz · 1×
Citations per year

Countries citing papers authored by M. Wouter Dercksen

Since Specialization
Citations

This map shows the geographic impact of M. Wouter Dercksen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Wouter Dercksen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Wouter Dercksen more than expected).

Fields of papers citing papers by M. Wouter Dercksen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Wouter Dercksen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Wouter Dercksen. The network helps show where M. Wouter Dercksen may publish in the future.

Co-authors

The 25 scholars most cited alongside M. Wouter Dercksen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with M. Wouter Dercksen Line = papers co-authored together M. Wouter Dercksen links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Less aggressive treatment and worse overall survival in cancer patients with diabetes: A large population based analysis
International Journal of Cancer ·Lonneke V. van de Poll‐Franse, Saskia Houterman, M.L.G. Janssen‐Heijnen, M. Wouter Dercksen, J.W.W. Coebergh, Harm R. Haak
2007271
2
Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome
Breast Cancer Research and Treatment ·D.J.A. Lobbezoo, Roel J.W. van Kampen, Adri C. Voogd, M. Wouter Dercksen, Franchette van den Berkmortel, Tineke J. Smilde, Agnès J. van de Wouw, Frank Peters, J.M.G.H. van Riel, Natascha A. J. B. Peters, Maaike de Boer, George F. Borm, Vivianne C. G. Tjan‐Heijnen
2013189
3
The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets
Nature Communications ·Job van Riet, Harmen J.G. van de Werken, Edwin Cuppen, Ferry A.L.M. Eskens, Margot Tesselaar, Linde M. van Veenendaal, Heinz‐Josef Klümpen, M. Wouter Dercksen, Gerlof D. Valk, Martijn P. Lolkema, Stefan Sleijfer, Bianca Mostert
202177
4
In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium
Annals of Oncology ·D.J.A. Lobbezoo, Roel J.W. van Kampen, Adri C. Voogd, M. Wouter Dercksen, F. Van den Berkmortel, TJ Smilde, Agnès J. van de Wouw, Frank Peters, J.M.G.H. van Riel, Natascha A. J. B. Peters, Maaike de Boer, P.G.M. Peer, V.C.G. Tjan-Heijnen
201548
5
Primary Granulocyte Colony-Stimulating Factor Prophylaxis During the First Two Cycles Only or Throughout All Chemotherapy Cycles in Patients With Breast Cancer at Risk for Febrile Neutropenia
Journal of Clinical Oncology ·Maureen J.B. Aarts, Frank Peters, Caroline M.P.W. Mandigers, M. Wouter Dercksen, Jacqueline M. Stouthard, Hans J. W. R. Nortier, Hanneke W.M. van Laarhoven, Laurence J. van Warmerdam, Agnès J. van de Wouw, Esther Jacobs, Vera Mattijssen, Carin C.D. van der Rijt, Tineke J. Smilde, Annette W. van der Velden, Mehmet Temizkan, Erdogan Batman, E.W. Muller, Saskia M. van Gastel, George F. Borm, Vivianne C. G. Tjan‐Heijnen
201338
6
Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01)
Annals of Oncology ·Ayoub Charehbili, Saskia van de Ven, Vincent T.H.B.M. Smit, Elma Meershoek‐Klein Kranenbarg, N.A.T. Hamdy, Hein Putter, Joan B. Heijns, L.J.C. van Warmerdam, Lonneke W. Kessels, M. Wouter Dercksen, Manon J. Pepels, E. Maartense, Hanneke W.M. van Laarhoven, Birgit E. P. J. Vriens, Martin N.J.M. Wasser, A. Elise van Leeuwen‐Stok, Gerrit‐Jan Liefers, C.J.H. van de Velde, J. W. R. Nortier, Judith R. Kroep
201431
7
Real-Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients: A Study of the Southeast Netherlands Breast Cancer Consortium
The Oncologist ·Shanly C. Seferina, D.J.A. Lobbezoo, Maaike de Boer, M. Wouter Dercksen, Franchette van den Berkmortel, Roel J.W. van Kampen, Agnès J. van de Wouw, Bart de Vries, Manuela Joore, Petronella G.M. Peer, Adri C. Voogd, Vivianne C. G. Tjan‐Heijnen
201530
8
Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer
JAMA Oncology ·Geert A. Cirkel, Paul Hamberg, Stefan Sleijfer, O. J. L. Loosveld, M. Wouter Dercksen, Maartje Los, Marco B. Polée, Franchette van den Berkmortel, Maureen J.B. Aarts, Laurens V. Beerepoot, Gerard Groenewegen, Martijn P. Lolkema, Metin Tascilar, (unknown), Frank Peters, Heinz‐Josef Klümpen, Vincent van der Noort, John B.A.G. Haanen, Emile E. Voest
201625
9
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry
The Lancet Regional Health - Europe ·Marissa Meegdes, Sandra M. E. Geurts, Frans Erdkamp, M. Wouter Dercksen, Birgit E. P. J. Vriens, Kirsten N. A. Aaldering, Manon J. Pepels, Linda M. H. van de Winkel, Natascha A. J. B. Peters, Jolien Tol, Joan B. Heijns, Agnès J. van de Wouw, Aude J.O. de Fallois, Maartje A.C.E. van Kats, Vivianne C. G. Tjan‐Heijnen
202319
10
Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: A study of the Southeast Netherlands Breast Cancer Consortium
Oncotarget ·Shanly C. Seferina, Bram Ramaekers, Maaike de Boer, M. Wouter Dercksen, Franchette van den Berkmortel, Roel J.W. van Kampen, Agnès J. van de Wouw, Adri C. Voogd, Vivianne Heijnen, Manuela Joore
201718
11
Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study
European Journal of Cancer ·Iris N. Poleé, B.C.M. Hermans, Jan Maarten van der Zwan, Stefan A.W. Bouwense, M. Wouter Dercksen, Ferry A.L.M. Eskens, Bastiaan Havekes, Johannes Hofland, Thomas Kerkhofs, Heinz‐Josef Klümpen, Loes M. Latten-Jansen, Ernst‐Jan M. Speel, Frederik A. Verburg, Annemiek Walenkamp, Sandra M. E. Geurts, Judith de Vos‐Geelen
202217
12
Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium
European Journal of Cancer ·Roel J.W. van Kampen, Bram Ramaekers, D.J.A. Lobbezoo, Maaike de Boer, M. Wouter Dercksen, F. Van den Berkmortel, Tineke J. Smilde, Agnès J. van de Wouw, Frank Peters, J.M.G. van Riel, Natascha A. J. B. Peters, V.C.G. Tjan-Heijnen, Manuela Joore
201712
13
Evaluation of Cohen's Cross-Section Trichometer for Measuring Hair Quantity
Dermatologic Surgery ·Maria A.E. Hendriks, Paulus A.F. Geerts, M. Wouter Dercksen, Corina van den Hurk, W.P.M. Breed
201211
14
The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2− advanced breast cancer patients: A study of the Dutch SONABRE Registry
International Journal of Cancer ·Marissa Meegdes, Sandra M. E. Geurts, Frans Erdkamp, M. Wouter Dercksen, Birgit E. P. J. Vriens, Kirsten N. A. Aaldering, Manon J. Pepels, Linda M. H. van de Winkel, N. Teeuwen, Maaike de Boer, Vivianne C. G. Tjan‐Heijnen
202110
15
The role of histological subtype in hormone receptor positive metastatic breast cancer: similar survival but different therapeutic approaches
Oncotarget ·D.J.A. Lobbezoo, Wilfred Truin, Adri C. Voogd, Rudi M. H. Roumen, Gerard Vreugdenhil, M. Wouter Dercksen, Franchette van den Berkmortel, Tineke J. Smilde, A. van de Wouw, Roel van Kampen, Johanna van Riel, Natascha A. J. B. Peters, Petronella G.M. Peer, Vivianne C. G. Tjan‐Heijnen
201610
16
Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry
Breast Cancer Research and Treatment ·Khava I. E. Ibragimova, Sandra M. E. Geurts, Marissa Meegdes, Frans Erdkamp, Joan B. Heijns, Jolien Tol, Birgit E. P. J. Vriens, M. Wouter Dercksen, Kirsten N. A. Aaldering, Manon J. Pepels, Linda van de Winkel, Natascha A. J. B. Peters, Nathalie J. A. Teeuwen-Dedroog, Ingeborg J. H. Vriens, Vivianne C. G. Tjan‐Heijnen
20237
17
Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)
Breast Cancer Research ·Stefanie de Groot, Hanno Pijl, Ayoub Charehbili, Saskia van de Ven, Vincent T.H.B.M. Smit, Elma Meershoek‐Klein Kranenbarg, Joan B. Heijns, L.J.C. van Warmerdam, Lonneke W. Kessels, M. Wouter Dercksen, Manon J. Pepels, Hanneke W.M. van Laarhoven, Birgit E. P. J. Vriens, Hein Putter, Marta Fiocco, Gerrit‐Jan Liefers, Jacobus J. M. van der Hoeven, J.W.R. Nortier, Judith R. Kroep
20197
18
Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry
Breast Cancer Research and Treatment ·Khava I. E. Ibragimova, Sandra M. E. Geurts, Sander Croes, Frans Erdkamp, Joan B. Heijns, Jolien Tol, Birgit E. P. J. Vriens, Kirsten N. A. Aaldering, M. Wouter Dercksen, Manon J. Pepels, Natascha A. J. B. Peters, Linda van de Winkel, D Tilli, Ingeborg J. H. Vriens, Maaike de Boer, Vivianne C. G. Tjan‐Heijnen
20217
19
Hair mass index obtained by cross-section trichometry: an objective and clinically useful parameter to quantify hair in chemotherapy-induced alopecia
Supportive Care in Cancer ·Rowena Vleut, Joyce E. A. M. van Poppel, M. Wouter Dercksen, Mijke Peerbooms, Saskia Houterman, W.P.M. Breed
20136
20
The prognostic impact of BMI in patients with HR+/HER2− advanced breast cancer: a study of the SONABRE registry
Breast Cancer Research and Treatment ·S W M Lammers, Hannah Thurisch, Ingeborg J. H. Vriens, Marissa Meegdes, Sanne Engelen, Frans Erdkamp, M. Wouter Dercksen, Birgit E. P. J. Vriens, Kirsten N. A. Aaldering, Manon J. Pepels, Linda M. H. van de Winkel, Natascha A. J. B. Peters, Jolien Tol, Joan B. Heijns, Agnès J. van de Wouw, N. Teeuwen, Sandra M. E. Geurts, Vivianne C. G. Tjan‐Heijnen
20235

About M. Wouter Dercksen

M. Wouter Dercksen is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Urology and Epidemiology, having authored 38 papers that have together received 862 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (7 papers), HER2/EGFR in Cancer Research (7 papers), Advanced Breast Cancer Therapies (5 papers), Hair Growth and Disorders (5 papers), Cancer Treatment and Pharmacology (3 papers), Metabolism, Diabetes, and Cancer (3 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Neuroendocrine Tumor Research Advances (2 papers). The work is most often cited by research in Oncology (327 citations), Cancer Research (125 citations), Pulmonary and Respiratory Medicine (183 citations), Urology (20 citations) and Epidemiology (99 citations). M. Wouter Dercksen has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Saskia Houterman, Harm R. Haak, Lonneke V. van de Poll‐Franse, M.L.G. Janssen‐Heijnen, J.W.W. Coebergh, Agnès J. van de Wouw, Maaike de Boer, Vivianne C. G. Tjan‐Heijnen, Roel J.W. van Kampen and D.J.A. Lobbezoo. Their work appears in journals such as Breast Cancer Research and Treatment, Annals of Oncology, European Journal of Cancer, The Breast and Supportive Care in Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by María Apellániz-RuizBreakdown of academic impact, for papers by Ramón PalmeroBreakdown of academic impact, for papers by Takeshi TomodaBreakdown of academic impact, for papers by Friedemann ZengerlingBreakdown of academic impact, for papers by Matthew R. ZibelmanBreakdown of academic impact, for papers by Gareth DaviesBreakdown of academic impact, for papers by Tsunehiro IshidaBreakdown of academic impact, for papers by Ertao ZhaiBreakdown of academic impact, for papers by A. RobinsonBreakdown of academic impact, for papers by Delphine Amsellem‐Ouazana